Australian Nobel Prize Winner Rules Out Biotech Work To Avoid Conflicts
This article was originally published in PharmAsia News
Australian scientist Peter Doherty says he will not work for biotech companies to avoid any conflicts of interest between advising the industry and engaging in public advocacy
You may also be interested in...
Following the US request for ranitidine drugs to be withdrawn from the market, the European Medicines Agency says it would decide the fate of the products in the EU after wrapping up its own inquiry.
Perrigo will launch generics of GSK's OTC Voltaren Arthritis Pain drug later in 2020 following FDA approval of its ANDA. GSK, which received FDA's OTC switch approval in February, still hasn't launched the product or indicated when it will.
Kline & Company’s worst-case scenario – which it says is looking more and more likely – has the US cosmetics and personal-care market declining by as much as 8.1% in 2020. However, Kline, Mintel and other market intelligence firms say there are opportunities available to companies struggling to weather the COVID-19 storm.